hosted by
publicationslist.org
    

Carmen Jeronimo

Research Center (CI-IPOP) of the
Portuguese Oncology Institute - Porto
& School of Medicine & Biomedical Sciences- University of Porto, Portugal
carmenjeronimo@ipoporto.min-saude.pt/ cljeronimo@icbas.up.pt
Carmen Jerónimo is the current Director of the Research Center of IPO Porto, Group Leader of the Cancer Biology & Epigenetics Group and the Scientific Coordinator of the Biobank at the Portuguese Oncology Institute of Porto (IPO Porto), as well as, Invited Full Professor in the Department of Pathology and Molecular Genetics and the Director of the Master Course in Oncology at the University of Porto, teaching Pathology and Cancer Epigenetics, both undergraduate and Post-graduation Courses.
Currently she is Visiting Professor of Dipartimento di Medicina di Precisione; Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy
She obtained her BSc in Biology (1994), MSc in Oncology (1998), PhD in Biomedical Sciences (2001) and Habilitation in Pathology and Molecular Genetics (2011) at the University of Porto. She performed her PhD project at Johns Hopkins University (JHU), USA under the GABBA Program, working on prostate cancer genetic and epigenetic alterations. From 2002 until 2007, she was a Post-doctoral Fellow and Invited Researcher at IPO Porto, in collaboration with JHU, working on the detection of neoplastic cells by DNA-based technology in clinical samples obtained from non-invasive or minimally invasive methods. In 2008 she established her independent group at IPO Porto, working on Cancer Biology and Epigenetics (FCT-2008 Science Program).
She has supervised 3 PhD students and co-supervised 5 PhD students, as well as supervised 38 master students and several undergraduate students. Presently she mentors 4 Junior Researchers, 5 PhD students, and 4 Master students.
As an independent Researcher, she served as Principal Investigator of 20 grants and participated in other 14 projects granted from different National and International agencies under competitive concurrence (Total Amount 2.3K€).
She has authored or co-authored more than 200 international scientific publications including five book chapters and several 50 review articles (H-index 44; Scopus 07/2020), including in first quartile (Q1) journals; Clin Cancer Res, Cancers, Cancer Letters, Cell Death Dis, Br J Cancer, Eur J Cancer, J Cell Mol Med, J Hematol Oncol, JNCI, Mol Cancer, Mol Oncol and Nat Commun, Oncogene, PNAS]. She has collaborated in a patent submission (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1).
Currently, she serves as Section Editor of Clinical Epigenetics and Associate Editor of International Journal of Molecular Sciences and Epigenomes, and she is also MC member of COST Action European Epitranscriptomics Network- CA16120-EPITRAN and Board member of ESUR- Section of Urological Research (ESUR) of European Association of Urology (EAU).
She usually acts as a grant reviewer for multiple national (FCT Investigator Call 2013 e 2015) and international agencies (2003-Health Research Board- HRB)-IR; 2006-Associazione Italiana per la Ricerca sul Cancro; 2006,2007-National Medical Research Council–Singapore; 2007,2015-Cancer ResearchUK; 2010-Binational Science Foundation Israel; 2011,2016,2018-Swiss National Science Foundation-SNSF; 2012-WILLIAMS BARKER,MRC,UK; 2013,2015-Swiss League Against Cancer-KFS; 2013,2015-FWF Austrian Science Fund; 2014-PROSTATE CANCER UK; 2016,2017-Fund for Scientific Research-FNRS–BL; 2019-Agence Nationale de la Recherche, FR; 2019-Fundaciò La Marató,SP).
Her research interests are focused on the characterization of the epigenome of tumor cells, and the identification of functional changes involved in cell epigenetic homeostasis breakdown. In the context of Personalized Medicine, she is works in the development of new of cancer epigenetic biomarkers based in liquid biopsies as well as in the drug discovery based on the modulation of epigenetic aberrations. Owing to the relevance that Immuno-oncology has demonstrated in recent years, she is also investigating the epigenetic expression modulation of biomolecules involved in immune checkpoint regulation, aiming at the improvement of immunotherapeutic strategies by combination with epi-drugs. More recently, she started tackling the contribution of deregulated non-coding RNAs and its interaction with other epigenetic mechanisms in malignant transformation.

http://www.cienciavitae.pt//CE16-29CB-EDD1;

http://www.scopus.com/inward/authorDetails.url?authorID=57197057169&partnerID=MN8TOARS;

http://orcid.org/0000-0003-4186-5345;

https://publons.com/researcher/1240765/carmen-jeronimo/

http://www.ipoporto.pt/en/ensino-investigacao/grupo-de-epigenetica-biologia-do-cancro/

http://www.icbas.up.pt

Powered by PublicationsList.org.